Esperion Posts Big Loss, But Drug Test Results PromisingEsperion Therapeutics Inc., (Nasdaq: ESPR), the pharmaceutical company developing promising new cholesterol therapies, reported a big loss for 2013 -- but continued promising clincal trial results.
Esperion Therapeutics Added To Nasdaq Biotech IndexEsperion Therapeutics Inc. (Nasdaq: ESPR) says its shares have been added to the Nasdaq Biotechnology Index effetive Dec. 23.
Esperion Therapeutics Presents Promising Test Results On Cholesterol DrugThe pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today's cholesterol-lowering statin drugs.
MVCA Honors VCs, Deals at Annual MeetingAt its annual meeting, the Michigan Venture Capital Association awarded its Best Financing award to Esperion Therapeutics, the MVCA 100 to FutureNet, Best Exit to Pioneer Surgical Technology and Lifetime Achievement to Tom Kinnear.
Esperion Starts Next Phase Of Cholesterol Drug TrialThe Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.
More Positive Test Results For Plymouth Firm's Cholesterol DrugEsperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
Esperion Therapeutics Reports Financial Details, Corporate UpdateEsperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
Esperion Stock Interest Strong, Underwriters’ Over-Allotment Option ExercisedEsperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
Esperion Therapeutics Going Public (Again) At $14 A Share
Esperion Gets Positive Results From New Study Of Cholesterol DrugEsperion Therapeutics Inc. Friday announced "positive" results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
Esperion Files For $70M IPOThe Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.
Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New DrugEsperion Therapeutics' proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.
Esperion Gets $33M To Continue Work On Cholesterol BusterThe Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.
Esperion Announces Positive Results From Phase 2 Trial Of Cholesterol Drug In Diabetes PatientsDiabetes patients who took a heart drug canadidate from Esperion Therapeutics, ETC 1002, found their so-called bad choleseterol, LDL-C, fall up to 43 percent, the company reported Monday.
Tim Mayleben Named President And CEO Of Esperion TherapeuticsEsperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, announced that Tim Mayleben has been named president and CEO of the company.